Edgewise Therapeutics, Inc. (EWTX) Research
Edgewise Therapeutics, Inc. is a biopharmaceutical firm dedicated to developing small-molecule treatments for a range of musculoskeletal disorders. Its leading investigational drug, EDG-5506, is an orally administered compound specifically engineered to tackle the fundamental genetic causes of dystrophinopathies, including Duchenne and Becker muscular dystrophy. This candidate has successfully concluded its Phase 1 clinical trial. Beyond EDG-5506, Edgewise maintains a pipeline of precision medicine candidates designed to modulate key muscle proteins, thereby addressing various genetically defined muscle conditions. Established in 2017, the company is headquartered in Boulder, Colorado.
Market snapshot
- Symbol
- EWTX
- Price
- $36.81
- Day change
- +5.72%
- Market cap
- $4.0B
- P/E ratio
- -22.40x
- 52-week range
- 12.15-40.765
- Sector
- Healthcare
- Industry
- Biotechnology
- Next earnings
- in 2 months
- Analyst price target
- $47.56
Recent news
- Edgewise Therapeutics Reports Improvements In Heart Drug Trial
Edgewise Therapeutics Inc. (NASDAQ:EWTX) on Tuesday released topline results from the 12-week Part D cohort of its Phase 2 CIRRUS-HCM trial.
- Edgewise shares slip after heart-disease drug trial data disappoints investors
Edgewise Therapeutics shares fell nearly 10% on Tuesday after the efficacy of its experimental heart-disease drug in a mid-stage study fell short of investor expectations.
- Edgewise to sell muscle dystrophy business to Servier for up to $2.65 billion
Biotech firm Edgewise Therapeutics said on Monday it would sell its experimental muscular dystrophy drug and related business to France's Servier for up to $2.65 billion.
Peer companies
Recent insider activity
- Brege Laura — A-Award (16377 shares) on 2026-06-05
- Thompson Peter A. — A-Award (16377 shares) on 2026-06-05
- Morris Arlene — A-Award (16377 shares) on 2026-06-05
- Edris Badreddin — A-Award (8188 shares) on 2026-06-05
- Edris Badreddin — A-Award (5619 shares) on 2026-06-05
Open Edgewise Therapeutics, Inc. (EWTX) in Thesis for live fundamentals, charts, options context, and portfolio-aware Copilot follow-ups.